Next Article in Journal
Correlation between Cyclosporine Blood Levels and Area under Blood Concentration Time Curve in Iraqi Bone Marrow Transplant Patients Treated with Neoral® Oral Solution
Previous Article in Journal
Cytotoxicity of Standardized Curcuminoids Mixture against Epithelial Ovarian Cancer Cell Line SKOV-3
Open AccessArticle

Pharmacokinetics and Dose Proportionality of Betahistine in Healthy Individuals

1
Department of Pharmacy, Al-Rasheed University College, Ministry of Higher Education and Scientific Research, Baghdad 10069, Iraq
2
College of Pharmacy, Alfarahidi University, Ministry of Higher Education and Scientific Research, Baghdad 10070, Iraq
*
Author to whom correspondence should be addressed.
Sci. Pharm. 2020, 88(1), 13; https://doi.org/10.3390/scipharm88010013
Received: 3 February 2020 / Revised: 29 February 2020 / Accepted: 2 March 2020 / Published: 11 March 2020
Betahistine dihydrochloride is widely used to reduce the severity and frequency of vertigo attacks associated with Ménière’s disease. Betahistine is an analogue of histamine, and is a weak histamine H1 receptor agonist and potent histamine H3 receptor antagonist. The recommended therapeutic dose for adults ranges from 24 to 48 mg given in doses divided throughout the day. Betahistine undergoes extensive first-pass metabolism to the major inactive metabolite 2-pyridyl acetic acid (2PAA), which can be considered a surrogate index for quantitation of the parent drug due to extremely low plasma levels of betahistine. The aim of the present investigation was to assess the pharmacokinetics and dose proportionality of betahistine in Arabic healthy adult male subjects under fasting conditions. A single dose of betahistine in the form of a 8, 16, or 24 mg tablet was administered to 36 subjects in randomized, cross-over, three-period, three-sequence design separated by a one week washout period between dosing. The pharmacokinetic parameters Cmax, AUC0–t, AUC0–∞, Tmax, and Thalf were calculated for each subject from concentrations of 2-PAA in plasma, applying non-compartmental analysis. The current study demonstrated that betahistine showed linear pharmacokinetics (dose proportionality) in an Arabic population over the investigated therapeutic dose range of 8–24 mg. View Full-Text
Keywords: betahistine; pharmacokinetics; dose proportionality; healthy Arabic subjects betahistine; pharmacokinetics; dose proportionality; healthy Arabic subjects
Show Figures

Figure 1

MDPI and ACS Style

Al-Tamimi, D.J.; Ammoo, A.M.; Alani, M.E.; Ibraheem, J.J. Pharmacokinetics and Dose Proportionality of Betahistine in Healthy Individuals. Sci. Pharm. 2020, 88, 13.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop